Literature DB >> 10714795

Clinical impact of rapid oxacillin susceptibility testing using a PCR assay in Staphylococcus aureus bactaeremia.

B Allaouchiche1, H Jaumain, G Zambardi, D Chassard, J Freney.   

Abstract

OBJECTIVES: The aim of this work was to establish the clinical impact of rapid oxacillin susceptibility testing in nosocomial Staphylococcus aureus bacteraemia.
METHODS: This study was performed in 145 critically ill patients infected by S. aureus. Patients were randomly assigned to one of two groups: patients for whom susceptibility testing was performed using a rapid same day multiplex PCR assay for detection of the staphylococcal mecA (mean delay of response: 6 h) and those for whom testing was accomplished using traditional overnight techniques (21 h).
RESULTS: The results of this study showed no significant difference between the two groups in terms of age, Simplified Acute Physiologic Score, severity of infection, severity of underlying disease and clinical outcome (control vs. PCR): unfavourable outcome of infection, 12.32 vs. 12.5%; 95% CI for the difference = -11.49 to 11.09 (P = 0.975); unfavourable general outcome, 16.43 vs. 20.83%; 95% CI for the difference = -17.35 to 8.50 (P = 0.497). For the oxacillin-susceptible S. aureus bactaeraemia, results were: unfavourable outcome of infection = 13.04 vs. 11.11%; 95% CI for the difference = -11.38 to 16.18 (P = 0.767); unfavourable general outcome = 13.04 vs. 20.37%; 95% CI for the difference = -22.12 to 8.07 (P = 0.331).
CONCLUSION: This study seemed to demonstrate that rapid oxacillin susceptibility testing using a PCR assay did not have a major impact on the care and outcome of patients with S. aureus bactaeremia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10714795     DOI: 10.1016/s0163-4453(99)90049-x

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Clinical impact of a PCR assay for identification of Staphylococcus aureus and determination of methicillin resistance directly from blood cultures.

Authors:  M Hallin; N Maes; B Byl; F Jacobs; Y De Gheldre; M J Struelens
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Impact of Xpert MRSA/SA blood culture PCR assay on management of positive blood cultures in obstetric patients: a retrospective audit.

Authors:  A Page; S O'Rourke; M Brennan; L Clooney; D Le Blanc; J Griffin; M Eogan; R J Drew
Journal:  Ir J Med Sci       Date:  2017-02-14       Impact factor: 1.568

3.  Methicillin-resistant Staphylococcus aureus: comparison of susceptibility testing methods and analysis of mecA-positive susceptible strains.

Authors:  G Sakoulas; H S Gold; L Venkataraman; P C DeGirolami; G M Eliopoulos; Q Qian
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  Evaluation of Bio-Rad MRSASelect agar for detection of methicillin-resistant Staphylococcus aureus directly from blood cultures.

Authors:  Stefan Riedel; Lisa Dam; Paul D Stamper; Syed A R Shah; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

5.  Detection of methicillin resistance and slime factor production of Staphylococcus aureus in bovine mastitis.

Authors:  Alper Ciftci; Arzu Findik; Ertan Emek Onuk; Serap Savasan
Journal:  Braz J Microbiol       Date:  2009-06-01       Impact factor: 2.476

Review 6.  Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.

Authors:  Stephanie S Buehler; Bereneice Madison; Susan R Snyder; James H Derzon; Nancy E Cornish; Michael A Saubolle; Alice S Weissfeld; Melvin P Weinstein; Edward B Liebow; Donna M Wolk
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

7.  Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection.

Authors:  Vanesa Anton-Vazquez; Paul Hine; Sanjeev Krishna; Marty Chaplin; Timothy Planche
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.